Selective effect of 2',6'-dihydroxy-4'-methoxychalcone isolated from Piper aduncum on Leishmania amazonensis

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 5, 1999, Pages 1234-1241

  Torres Santos, Eduardo Caio ^a   Moreira, Davyson Lima ^a   Kaplan, Maria Auxiliadora C ^a   Meirelles, Maria Nazareth ^b   Rossi Bergmann, Bartira ^a,b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

2',6' DIHYDROXY 4' METHOXYCHALCONE; CHALCONE; NITRIC OXIDE; PIPER ADUNCUM EXTRACT; UNCLASSIFIED DRUG;

AMASTIGOTE; ANTIMICROBIAL THERAPY; ARTICLE; DRUG ACTIVITY; DRUG EFFECT; GROWTH INHIBITION; LEISHMANIA; LEISHMANIASIS; MACROPHAGE; MICROBIAL GROWTH; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROMASTIGOTE;

EID: 0032908492     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.5.1234     Document Type: Article

References (40)

1. Albrecht, H., I. Sobottka, C. Emminger, H. Jablonowski, G. Just, A. Stoehr, T. Kubin, B. Salzberger, T. Lutz, and J. van Lunzen. 1996. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Arch. Pathol. Lab. Med. 120:189-198.
2. Alvar, J. 1994. Leishmaniasis and AIDS co-infection: the Spanish example. Parasitol. Today 10:160-163.
3. Anto, R. J., K. Sukumaran, G. Kuttan, M. N. Rao, V. Subbaraju, and R. Kuttan. 1995. Anticancer and antioxidant activity of synthetic chalcones and related compounds. Cancer Lett. 97:33-37.
4. Ashford, R. W., P. Desjeux, and P. de Raadt. 1992. Estimation of population at risk of infection and number of cases of leishmaniasis. Parasitol. Today 8:104-105.
5. Berman, J. D. 1997. Human leishmaniasis: clinical, diagnostic and chemotherapeutic developments in the last ten years. Clin. Infect. Dis. 24:684-703.
6. Chen, M., S. B. Christensen, J. Blom, E. Lemmich, L. Nadelmann, K. Fich, T. G. Theander, and A. Kharazmi. 1993. Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania. Antimicrob. Agents Chemother. 37:2550-2556.
7. Chen, M., S. B. Christensen, T. G. Theander, and A. Kharazmi. 1994. Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani. Antimicrob. Agents Chemother. 38:1339-1344.
8. Croft, S. L. 1994. A rationale for antiparasite drug discovery. Parasitol. Today 10:385-386.
9. Croft, S. L., J. A. Urbina, and R. Brun. 1997. Chemotherapy of human leishmaniasis and trypanosomiasis, p. 245-257. In G. Hide, J. C. Mottram, G. H. Coombs, and P. H. Holmes (ed.), Trypanosomiasis and leishmaniasis. CAB International, London, United Kingdom
10. Da Silva, S. A., G. S. S. Costa, and B. Rossi-Bergmann. The anti-leishmanial effect of Kalanchoe is mediated by nitric oxide intermediates. Parasitology, in press.
11. Dewindt, B., K. van Eemeren, and K. Andries. 1994. Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses. Antivir. Res. 25:67-72.
12. Ding, A. H., C. F. Nathan, and D. J. Stuehr. 1988. Release of reactive nitrogen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 141:2407-2412.
13. Duke, J. A. 1985. Handbook of medicinal herbs. CRC Press, New York, N.Y.
14. Green, S. J., M. S. Meltzer, J. R. Hibb, and C. Nacy. 1990. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J. Immunol. 144:278-283.
15. Grimaldi, G. J. 1995. Meetings on vaccine studies towards the control of leishmaniasis. UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR). Mem. Inst. Oswaldo Cruz 90:553-556.
16. Handman, E. 1997. Leishmania vaccines: old and new. Parasitol. Today 13:236-238.
17. Hepburn, N. C., I. Siddique, A. F. Howie, G. J. Beckett, and P. C. Hayes. 1994. Hepatotoxicity of sodium stibogluconate therapy for American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 88:453-455.
18. Holdsworth, D., and F. Damase. 1986. Medicinal plants of Morobe Province, Papua New Guinea. Int. Guide Drug Res. 24:217.
19. Iwu, M. M., J. E. Jackson, and B. G. Schuster. 1994. Medicinal plants in the fight against leishmaniasis. Parasitol. Today 10:65-68.
20. Kharazmi, A., M. Chen, T. G. Theander, and S. B. Christensen. 1997. Discovery of oxygenated chalcones as novel antimalarial agents. Ann. Trop. Med. Parasitol. 91:S91-S95.
21. Kirby, G. C. 1996. Medicinal plants and the control of protozoal disease, with particular reference to malaria. Trans. R. Soc. Trop. Med. Hyg. 90:605-609.
22. Lemesre, J.-L., D. Sereno, S. Daulouede, B. Veyret, N. Brajon, and P. Vincendeau. 1997. Leishmania spp.: nitric oxide-mediated metabolic inhibition of promastigole and axenically grown amastigote forms. Exp. Parasitol. 86: 56-68.
23. Liew, F. Y, and F. E. G. Cox. 1991. Nonspecific defense mechanism: the role of nitric oxide. Immunoparasitol. Today 1991:A17-A21.
24. Liew, F. Y., S. Millot, C. Parkinson, R. M. J. Palmer, and S. Moncada. 1990. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J. Immunol. 144:4794-4797.
25. Maarouf, M., Y. de Kouchkovsky, S. Brown, P. X. Petit, and M. Robert-Gero. 1997. In vivo interference of paromomycin with mitochondrial activity of Leishmania. Exp. Cell Res. 232:339-348.
26. Mauel, J., and A. Ransijn. 1997. Leishmania spp. Mechanisms of toxicity of nitrogen oxidation products. Exp. Parasitol. 87:98-111.
27. Moreira, D. L., E. F. Gimarães, and M. A. C. Kaplan. 1998. A chromene from Piper aduncum L. Phytochemistry 48:1075-1077.
28. Neal, R. A., S. Allen, N. McCoy, P. Olliaro, and S. L. Croft. 1995. The sensitivity of Leishmania species to aminosidine. J. Antimicrob. Chemother. 35:577-584.
29. Okunade, A. L., C. D. Hufford, A. M. Clark, and D. Lentz. 1997. Antimicrobial properties of the constituents of Piper aduncum. Phytother. Res. 11:142-144.
30. Olliaro, P. I., and D. M. Bryceson. 1993. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol. Today 9:323-328.
31. Romāo, P. R. T., S. A. Antoniazi, H. C. Lima, A. K. Cruz, and F. Q. Cunha. 1997. Is glutathione an important virulence factor in leishmaniasis? Mem. Inst. Oswaldo Cruz 92(Suppl. I):219.
32. Rossi-Bergmann, B., and G. Noleto. 1994. A low-cost and efficient procedure for harvesting DNA-labeled cells using a dot-blot apparatus. BioTechniques 17:678-680.
33. Rossi-Bergmann, B., S. S. Costa, M. B. S. Borges, S. A. Da Silva, G. Noleto, M. L. M. Souza, and V. L. G. Moraes. 1994. Immunosuppressive effect of the aqueous extract of Kalanchoe pinnata in mice. Phytother. Res. 8:399-402.
34. Science. 1990. Medicine from plants. Science 247:513. (Editorial.)
35. Sereno, D., M. Cavaleyra, K. Zemzoumi, S. Maquaire, A. Ouaissi, and J. L. Lemesre. 1998. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob. Agents. Chemother. 42:3097-3102.
36. Stenger, S., H. Thuring, M. Rollinghoff, and C. Bogdan. 1994. Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major. J. Exp. Med. 180:783-789.
37. Urbina, J. A. 1997. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 114:S91-S99.
38. Yang, D. M., and F. Y. Liew. 1993. Effects of qinghaosu (artemisinin) and its derivatives on experimental cutaneous leishmaniasis. Parasitology 106:7-11.
39. Zhai, L., J. Blom, M. Chen, S. B. Christensen, and A. Kharazmi. 1995. The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria. Antimicrob. Agents. Chemother. 39:2742-2748.
40. Zhang, K., E. B. Yang, W. Y. Tang, K. P. Wong, and P. Mack. 1997. Inhibition of glutathione reductase by plant polyphenols. Biochem. Pharmacol. 54:1047-1053.